CORRECTION Open Access

Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Ho Jin Lee^{1,2†}, Phuong Chi Pham^{2†}, Seung Yeob Hyun^{1,2}, Byungyeob Baek², Byungjin Kim², Yunha Kim², Hye-Young Min^{1,3}, Jeeyeon Lee^{2*} and Ho-Young Lee^{1,2,3*}

Correction: Mol Cancer 17, 50 (2018) https://doi.org/10.1186/s12943-018-0802-4

In our publication in Molecular Cancer entitled 'Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity [Mol Cancer 17, 50 (2018); doi: 10.1186/s12943-018-0802-4]' [1], we regret the errors in Fig. 2b in the printed version. In detail, the western blot images in Fig. 2b (Src blots in the A549 group and Actin blots in the H1299 group) were inadvertently placed by mistake. We have double-checked the original data and found that the inadvertent errors occurred during image assembling.

The corrected Fig. 2 is given here, and this correction does not change the scientific conclusions of the article.

We sincerely apologize for any inconveniences these mistakes may have caused.

Published online: 08 March 2023

Reference

Lee HJ, Pham PC, Hyun SY, et al. Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity. Mol Cancer. 2018;17:50. https://doi.org/10.1186/s12943-018-0802-4.

 $^{\dagger}\mbox{Ho}$ Jin Lee and Phuong Chi Pham contributed equally to this work.

The original article can be found online at https://doi.org/10.1186/s12943-018-0802-4.

*Correspondence: Jeeyeon Lee jyleeut@snu.ac.kr Ho-Young Lee hylee135@snu.ac.kr

¹ Creative Research Initiative Center for Concurrent Control of Emphysema and Lung Cancer, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea

² College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea

³ Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, and College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/loublicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data

Lee et al. Molecular Cancer (2023) 22:47 Page 2 of 2




Fig. 2 Inhibitory effect of LL28 on the activation of both IGF1R and Src. **a** A549 cells were treated with linsitinib (1 μM), dasatinib (100 nM), or LL28 (1 μM) for 4 h. Before harvesting, cells were stimulated with FBS for 20 min. The expression of total and phosphorylated IGF1R and Src was evaluated by Western blot analysis. **b** and **c** A549, H1299, and H460 cells were treated with LL28 (0.1 and 1 μM) for 8 h (**b** and **c**) or 1.5 days (**c**). **b** The expression of total and phosphorylated IGF1R and Src was evaluated by Western blot analysis. **c** The expression of the total and phosphorylated forms of several kinases was evaluated by Western blot analysis. **d** Total cell lysates of A549 cells treated with LL28 for 8 h were immunoprecipitated with anti-IGF1R or anti-IR antibodies. **The immunoprecipitants** were further subjected to Western blot analysis using anti-pTyr, anti-IGF1R, and anti-IR antibodies. **e** R- cells were treated with LL28 (0.1 and 1 μM) for 8 h. The expression of total and phosphorylated IGF1R and Src was determined by Western blot analysis. **f** A549 cells were treated with linsitinib (1 μM) or dasatinib (100 nM) for 1 day. The expression of total and phosphorylated IGF1R and Src was evaluated by Western blot analysis. **g** A549, H1299, and H460 cells were treated with LL28 (0.1 μM) for 1, 3, and 5 days. The expression of total and phosphorylated IGF1R and Src was evaluated by Western blot analysis. Con: control; Lin: linsitinib; Das: dasatinib